Isoray, Inc., operating through its subsidiary IsoRay Medical, Inc., specializes in the development, production, and sale of isotope-based medical devices and products. These offerings are designed for the treatment of cancer and other malignant diseases, distributed across both the United States and international markets. A key product is their CS-1 Cesium-131 brachytherapy seeds, utilized in addressing a variety of cancers, including those of the prostate, brain, lung, head and neck, as well as gynecological, pelvic/abdominal, and colorectal malignancies. The company distributes its products to medical facilities or physician practices that conduct surgical operations. Founded in 1998, Isoray, Inc. is headquartered in Richland, Washington.